- Home
- IRON
IRON
Disc Medicine Inc.
as 11-15-2024 4:00pm EST
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $72.00 | AVG Volume (30 days): | 431.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.60 - $77.60 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Disc Medicine Inc. (IRON)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| White William Richard | IRON | Director | Oct 1 '24 | Sell | $50.88 | 201 | $10,312.44 | 0 | |
| Savage William Jacob | IRON | Chief Medical Officer | Sep 16 '24 | Sell | $47.41 | 1,500 | $71,115.00 | 40,405 | |
| White William Richard | IRON | Director | Sep 3 '24 | Sell | $50.89 | 1,957 | $97,158.24 | 0 | |
| Savage William Jacob | IRON | Chief Medical Officer | Sep 3 '24 | Sell | $50.59 | 1,500 | $75,885.00 | 40,405 |
Latest Disc Medicine Inc. News
IRON Breaking Stock News: Dive into IRON Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Disc Medicine to Participate in Upcoming Investor Conferences
MT Newswires
5 days ago
Wedbush Raises Disc Medicine Price Target to $83 From $75, Maintains Outperform Rating
MT Newswires
5 days ago
Disc Medicine's Q3 Net Loss Widens
GlobeNewswire
5 days ago
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
Clinical Trials Arena
6 days ago
Disc Medicine secures $200m financing to support trials
MT Newswires
9 days ago
Disc Medicine Gets $200 Million Loan From Hercules Capital
GlobeNewswire
9 days ago
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
GlobeNewswire
12 days ago
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Compare IRON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRON Disc Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.